Relievant Medsystems is a commercial-stage medical device company that developed and commercialized the Intracept Intraosseous Nerve Ablation System, the only FDA-cleared treatment for chronic vertebrogenic low back pain. The minimally invasive, implant-free outpatient procedure uses targeted radiofrequency energy to ablate the basivertebral nerve, stopping it from transmitting pain signals to the brain. Relievant was acquired by Boston Scientific in November 2023 and operates as part of its neuromodulation business.
Relievant Medsystems has been acquired
This company is no longer available on our private secondary market.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2006
Total Funding
$273M
1 rounds
Total raised $273M across 1 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 05-09-2026
Latest Round
Type
Series G
Date
April 19, 2023
Amount
$50M
Valuation
—
Lead Investors
Tyler Binney
President and Chief Executive Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Stryker (OptaBlate BVN)
Stryker received FDA 510(k) clearance in May 2025 for its OptaBlate BVN Basivertebral Nerve Ablation System, a minimally invasive procedure for chronic vertebrogenic low back pain that competes directly with Intracept.
Medtronic (ViaVerte)
Medtronic's ViaVerte is an FDA-cleared, minimally invasive, implant-free basivertebral nerve ablation system for chronic vertebrogenic low back pain, distributed in partnership with Merit Medical Systems.
Abbott Laboratories
Abbott's neuromodulation business markets spinal cord stimulation systems (e.g., Proclaim, Eterna) for chronic back pain, an alternative therapeutic pathway for patients who would otherwise be candidates for Intracept.
Nevro Corp
Nevro develops the Senza HF10 spinal cord stimulation platform for chronic back and leg pain, competing as an alternative chronic-low-back-pain treatment to vertebrogenic-targeted therapies.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.